Chlormadinone acetate (CMA) in oral contraception – A new opportunity

References

• , et al. Update on progestogen therapy. J Reprod Med 1999; 44: 139–232, Fraser IS, Lobo R (eds)
   PubMed Web of Science ®Google Scholar
• Bell E T, Christie B W. Gonadotrophin and steroid interrelationships during the normal menstrual cycle. Steroidologia 1970; 1: 152–174
   PubMedGoogle Scholar
• O'Malley B W, Sherman M R, Toft D O. Progesterone “receptors” in the cytoplasm and nucleus of chick oviduct target tissue. Proc Natl Acad Sci USA 1970; 67: 501–508
   PubMed Web of Science ®Google Scholar
• Edwards D P, Weigel N L, Schrader W T, O'Malley B W, McGuire W L. Structural analysis of chicken oviduct progesterone receptor using monoclonal antibodies to the subunit B protein. Biochemistry 1984; 23: 4427–4435
   PubMed Web of Science ®Google Scholar
• O'Malley B W. A life-long search for the molecular pathways of steroid hormone action. Mol Endocrinol 2005; 19: 1402–1411
   PubMed Web of Science ®Google Scholar
• O'Malley B W, Schrader W T. Progesterone receptor components: identification of subunits binding to the target-cell genome. J Steroid Biochem 1972; 3: 617–629
   PubMedGoogle Scholar
• Giangrande P H, McDonnell D P. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 1999; 54: 291–313
   PubMedGoogle Scholar
• Vegeto E, Shahbaz M M, Wen D X, Goldman M E, O'Malley B W, McDonnell D P. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993; 7: 1244–1255
   PubMed Web of Science ®Google Scholar
• Wen D X, Xu Y F, Mais D E, Goldman M E, McDonnell D P. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 1994; 14: 8356–8364
   PubMed Web of Science ®Google Scholar
• Leo J C, Guo C, Woon C T, Aw S E, Lin V C. Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology 2004; 145: 1314–1321
   PubMed Web of Science ®Google Scholar
• Dorfman R I, Forchielli E, Gut M. Androgen biosynthesis and related studies. Recent Progr Hormone Res 1963; 19: 251–273
   PubMedGoogle Scholar
• Kraft H G, Kiesler H. Anti-estrogenic and anti-androgenic activities of chlormadinone acetate and related compounds. Proceedings of the Second International Congress on Hormonal Steroids, V HT James, L Martini. Excerpta Medica, Milano 1966
   Google Scholar
• Kuhl H. Chemie und Pharmakologie von Chlormadinoneacetat. Chlormadiononeacetat bei Androgenisierungserscheinungen, E G Loch, G Schramm, Schattauer 1995; 1–12
   Google Scholar
• Saunders D M, Stewart M L, Brij B S, et al. Effect of daily administration of 0.5 mg of chlormadinone acetate on plasma levels of follicle-stimulating hormone, luteinizing hormone, and progesterone during the menstrual cycle. Fertil Steril 1971; 22: 332–344
   PubMed Web of Science ®Google Scholar
• Orr A H, Elstein M. Luteinizing hormone levels in plasma and urine in women during normal menstrual cycles and in women taking combined contraceptives or chlormadinone acetate. J Endocrinol 1969; 43: 617–624
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171–197
   PubMed Web of Science ®Google Scholar
• Larsson-Cohn U, Johansson E D, Wide L, et al. Effects of continuous daily administration of 0.5 mg of chlormadinone acetate on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens. Acta Endocrinol (Copenh) 1970; 63: 705–716
   PubMedGoogle Scholar
• Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003; 63: 463–492
   PubMed Web of Science ®Google Scholar
• Grünenthal G mbH. Belara®: Highlights of the product's properties, , et al. Product Monograph, Aachen 2001
   Google Scholar
• Gallegos A J, Gonzalez-Diddi M, Merino G, et al. Tissue localization of radioactive chlormadinone acetate and progesterone in the human. Contraception 1970; 1: 151–161
   Google Scholar
• Honma S, Iwamura S, Iizuka K, Kambegawa A, Shida K. Identification and anti-androgenic activity of the metabolites of 17alpha-acetoxy-6-chloropregna-4,6-diene-3,20-dione (chlormadinone acetate) in the rat, rabbit, dog and man. Chem Pharm Bull (Tokyo) 1977; 25: 2019–2031
   PubMed Web of Science ®Google Scholar
• Chassard D, Legallicier P, Dib M. Etude de la biodisponibilite relative de deux formations orales d'acetate de chlormadinone: Luteran 5mg and Luteran comprime dose a 10 mg. Therapie 2003; 58: 127–131
   PubMedGoogle Scholar
• Terlinden R, Uragg H, Göhler K, Kneip C. Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg), poster presented at SEG 2005, , et al. Helsinki
   Google Scholar
• Kuhl H, Jung-Hoffmann C. Pharmakologie der Gestagene. Kontrazeption, H Kuhl, C Jung-Hoffmann. Thieme, Stuttgart 1999; 28–31
   Google Scholar
• Pélisser C, Blacker M C, Feinstein M C, Cournot A, Dennis C. Anti-ovulatory action of chlormadinone acetate [in French]. Contracept Fertil Sex 1994; 22: 37–40
   PubMedGoogle Scholar
• Chassard D, Schatz B. The antigonadotrophic activity of chlormadinone acetate in reproductive women [in French]. Gynecol Obstet Fert 2005; 33: 29–35
   PubMedGoogle Scholar
• Johnson A N. Comparative aspects of contraceptive steroids – effects observed in beagle dogs. Toxicol Pathol 1989; 17: 389–395
   PubMed Web of Science ®Google Scholar
• Conard J, Plu-Bureau G, Bahi N, Horellou M H, Pélisser C, Thalabard J C. Progestogen-only contraception in women at high risk of thromboembolism. Contraception 2004; 70: 437–440
   PubMed Web of Science ®Google Scholar
• Pélisser C, Basdevant A, Conard J, et al. Long-lasting administration of chlormadinone acetate effects on the metabolism, blood pressure and hormones. Gynécologie 1991; 42: 79–86
   Google Scholar